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The overall prognosis of patients with advanced melanoma is poor due to the 
lack of effective treatment. A key factor for successful therapy is an early 
detection of disease. Therefore reliably detection methods and meaningful 
tumor markers are required. Expression of the human endogenous retrovirus 
(HERV)-K(HML-2) was found elevated in melanomas and it was shown that 
HERV-K supports the in vitro transition of melanoma cells from adherent to a 
more malignant, non-adherent phenotype. Furthermore, detection of HERV-K-
specific antibodies in melanoma patients was found to correlate with reduced 
survival. However, the reason for HERV-K expression in melanomas still 
remains unclear and its use as a tumor marker needs further investigation. 
Therefore, the tumor-specific transcriptional regulation of HERV-K expression 
in melanoma was studied in detail. Human melanoma cell lines were 
investigated for HERV-K expression using real-time PCR. Five cell lines 
showed very high levels of HERV-K mRNA as a result of increased promoter 
activity. This promoter activity was directly silenced by DNA methylation in 
reporter gene experiments. Higher levels of long terminal repeat (LTR) 
methylation in cells not expressing HERV-K compared with cells expressing 
HERV-K were found using methylation-sensitive PCR and bisulfite sequencing. 
Treatment of cell lines with the demethylating agent 5-aza-2'-deoxycytidine 
resulted in increased levels of HERV-K expression in cells previously not 
expressing HERV-K and it was shown that this increase is not the result of 
transcription factor activation. These results demonstrate that increased 
HERV-K expression in melanomas may be due to increased promoter activity 






The human genome comprises approximately 60 full-length HERV-K(HML-2) 
proviruses and about 2500 HERV-K solo long terminal repeats (LTR) (Gifford and Tristem, 
2003; Mager and Medstrand, 2003). The origin of these proviruses and LTR elements were 
retroviral infections of germ-line cells before and during primate evolution and subsequent 
amplification inside the host via retrotransposition, reinfection and complementation in trans. 
As a consequence of mutations, deletions and internal homologous recombination most of 
these retroviral elements lost their replication capability and infectivity. But open reading 
frames and viral protein expression can still be found and there is accumulating evidence that 
HERVs play a direct role in tumor induction and progression as well as in physiological 
processes (Boese et al., 2000; Denne et al., 2007; Serafino et al., 2009; Denner, 2010). 
The family of HERV-K(HML-2) can be subdivided into type 1 and type 2 proviruses. 
Type 1 proviruses are characterized by a 292 base pair (bp) deletion at the pol-env boundary 
and an open reading frame (ORF) for the nonstructural protein Np9 (Armbruester et al., 
2002). Type 2, the undeleted prototype, has an intact env sequence and encodes the accessory 
protein Rec (Lower et al., 1993, 1995). Both proteins were found expressed in tumors and 
transformed cell lines and evidence has accumulated that they play a role in cancer 
development. Rec and Np9 directly bind to the promyelocytic leukemia zinc finger (PLZF) 
protein and inhibit the transcriptional inhibiting function of PLZF. As a result the MYC 
promoter loses its repressed state and MYC expression is promoting cellular proliferation 
(Denne et al., 2007). In addition, mice that were transgenic for Rec showed a development of 
carcinoma in situ, an early marker for testicular cancer (Galli et al., 2005). Expression of 
HERV-K(HML-2) mRNA and protein was found in germ cell tumors (Lower et al., 1984; 
Herbst et al., 1998), in melanomas (Muster et al., 2003; Buscher et al., 2005, 2006) and in 
human breast carcinomas (Wang-Johanning et al., 2003). A matter of particular interest is the 
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expression of HERV-K(HML-2) in human melanomas. The presence of anti-HERV-K 
antibodies in early stages of the disease was shown to be a marker of reduced survival (Hahn 
et al., 2008). Furthermore, HERV-K was reported to support the in vitro transition of 
melanoma cells from adherent to a more malignant, non-adherent phenotype when exposed to 
stress conditions (Serafino et al., 2009).  
The regulation of HERV-K(HML-2) expression in melanomas is unclear. Besides 
transcriptional regulation via transcription factors (TFs) (Ono et al., 1987; Akopov et al., 
1998; Knossl et al., 1999; Kwun et al., 2002), an epigenetic regulation via DNA-methylation 
was reported in teratocarcinomas (Gotzinger et al., 1996). A correlation between methylation 
of the U3 region of the HERV-K(HML-2) 5’LTR and the transcriptional activity of the LTR 
was shown (Lavie et al., 2005).  
To understand the high transcriptional activity of HERV-K(HML-2) proviruses in 
melanomas and to demonstrate their cancer specific expression, we investigated the regulation 
of these retroviral elements in more detail. A panel of human melanoma cell lines was 
analyzed for HERV-K-expression, promoter activity and the methylation status of the 5'LTR. 
Based on these data it was shown that cells with high HERV-K-expression compared to cells 
with basal levels of HERV-K mRNA exhibited genetic and epigenetic changes. High levels of 
HERV-K expression were only found in melanoma cell lines that also showed a high HERV-
K promotor activity. In addition, those cell lines exhibited low levels of LTR methylation. In 
line with this cell lines not expressing HERV-K showed stronger methylation of 5'LTRs and 
expression could be stimulated by treatment with the demethylating agens 5-aza-dC. 
Therefore, melanoma cell lines that showed high levels of HERV-K expression must have lost 
methylation and, in addition, a deregulation of HERV-K specific TFs must have occurred. 
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MATERIALS AND METHODS 
Cell Lines and Treatments 
 The SK-MEL-13 and SK-MEL-19 melanoma cell lines were obtained from Dr. 
J. Eberle (Department of Dermatology, Charité-Universitätsmedizin, Campus Benjamin 
Franklin, Berlin, Germany), and the SK-MEL-24 and SK-MEL-37 were a gift from Dr. Peter 
Walden (Department of Dermatology, Charité Campus Mitte, Berlin, Germany). The cell 
lines were cultured as described previously (Bredenbeck et al., 2005; Fecker et al., 2005). The 
human melanoma cell lines SK-MEL-28, SchM, SchW, TR, ZO, KU, RA, and ZD, the human 
embryonic kidney cell line 293, the human teratocarcinoma cell line GH and the isolation of 
PBMCs have been described previously (Buscher et al., 2005). HEK-293 and melanoma cell 
lines were treated with 2 µM 5-aza-dC (Sigma Aldrich, Germany) and 50 nM trichostatin A 
(Sigma Aldrich) and GH cells with 1 µM 5-aza-dC and 25 nM trichostatin A. The drug 
containing medium was renewed every day and cells were harvested after 3 days of treatment. 
  
RNA and DNA Preparation 
Total RNA and genomic DNA from cell cultures were isolated using RNeasy and 
DNeasy Kits, respectively, according to manufacturer’s instructions (Qiagen, Hilden, 
Germany). Quality and quantity of both RNA and DNA were determined by 1% agarose gels 
and photometry. 
 
Quantitative Real-Time RT-PCR 
500 – 2000 ng of total RNA were reverse transcribed using the RevertAid™ H Minus 
M-MuLV Reverse Transcriptase Kit (Fermentas, St. Leon-Rot, Germany) and Random 
Hexamer Primer according to manufacturer's protocols. Then the reaction products were 
diluted 1:10 and 1µl was used for performing quantitative real-time PCR using the Brilliant 
SYBR® Green QPCR Master Mix and the Mx4000® QPCR System (Stratagene, Germany). 
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For detection of HERV-K(HML-2) env mRNA the primer pair Pfor/Penv, for detection of the 
rec mRNA the primer pair Pfor/Prec and for detection of np9 mRNA the primer pair 
Pfor/Pnp9 was used. Within each experiment the housekeeping gene GUSB was used for data 
normalization (for primer sequences see supplemental material Table 1). 
 
HERV-K108 LTR Luciferase Promoter Reporter Construct 
The 5’LTR reporter construct was generated by cloning a PCR fragment starting at 
position -283 bp upstream of the 5’LTR of HERV-K provirus K108 until position +1255 bp. 
Following PCR, amplicons were subcloned into the luciferase vector pGL3-Basic (Promega, 
Mannheim, Germany) and subclones were verified by DNA sequencing.  
 
Dual Luciferase Reporter Gene Assay 
Luciferase activity was measured after transient transfection of the pGL3 basic vector 
(determination of background luciferase activity), the pGL3-LTR vector (analyzing LTR-
activity) and the pGL3-control vector (positive control). To normalize the transfection 
efficiency, a cotransfection of the renilla luciferase expression vector pRL-CMV was 
performed. For transfection experiments, 2x105 cells were cultured overnight in 48 well tissue 
culture plates. Luciferase reporter plasmids were added together with Lipofectamine 2000 
according to manufacturer’s protocols (Invitrogen, Karlsruhe, Germany). All experiments 
were performed at least in triplicates. Measurement of luciferase expression was done 
according to manufacturer's protocols (Promega). 
 
In Vitro DNA Methylation. 
The 5’LTR/reporter construct was methylated by SssI DNA methylase according to 
supplier’s instructions (New England Biolabs, Frankfurt, Germany). Four different amounts 
of SssI DNA methylase (0 U, 0.75 U, 2 U, 4 U) were used for generating different levels of in 
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vitro methylated reporter plasmids. For each reaction sample, 6 µg of plasmid-DNA was 
incubated in 30 µl of 1xNE buffer 2 for 4 hr at 37°C. The reaction was terminated by heat 
inactivation (65°C for 20 min) and the samples were purified using the Qiagen QIAquick® 
PCR Purification Kit (Qiagen). Control of methylation was performed with the methylation 
sensitive restriction enzyme HpaII according to the manufacturer's manual (New England 
Biolabs). 
 
Methylation Analysis by Genomic Sequencing 
Sodium bisulfite treatment was performed as previously described (Frommer et al., 
1992). Locus-specific nested PCR was performed using primer pairs BSS-K108-183fw/BSS-
K108+1306rev and BSS-K108-40fw/BSS-K108+1121rev under conditions described 
elsewhere (Schenk et al., 2007). PCR amplification was performed for 32 cycles of 30 sec at 
95°C, 20 sec at 55°C and 200 sec at 72°C. The second amplification step was carried out 
using 1/100 of the first PCR product for 32 cycles of 30 sec at 95°C, 20 sec at 55°C and 180 
sec at 72°C. Then the PCR-fragments were subcloned into a TA-Cloning vector. 
Transformation into E.coli Top10 F' competent cells was performed with CaCl2. Plasmid 
DNA was prepared from transformed clones and sequenced using M13-promotor-primers and 
the ABI BigDye 3.1-Mastermix (ABI Terminator Chemie, Applied Biosystems, Darmstadt, 
Germany). 
 
Methylation Analysis by Methylation Sensitive Restriction Endonucleases 
200 ng of genomic DNA from each cell line were digested over night in 30 µl reaction 
volume using the methylation sensitive endonucleases HpaII, BsaAI (New England Biolabs) 
and TauI (Fermentas, St. Leon-Rot, Germany), according to the manufacturer's protocols. 
Each reaction batch also contained 1 U EcoRI (New England Biolabs) for uniformly shearing 
of genomic DNA (no restriction site within the HERV-K 5’LTR). For normalization of the 
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PCR reaction 200 ng genomic DNA were digested by EcoRI without the addition of 
methylation sensitive endonucleases. After digestion, 1 µl of the reaction volume was added 
to 14 µl of PCR mixture containing 1.5 µl of GeneAmp 10X PCR Gold Buffer  (Applied 
Biosystems), 5% DMSO, 200 µM of each of the four deoxynucleoside triphosphates, 0.2 µM 
of HERV-K(HML-2) locus specific primers and 0.5 U of AmpliTaq Gold DNA Polymerase 
(Applied Biosystems). PCR amplification was performed for 28 cycles of 30 sec at 95°C, 20 
sec at 60°C and 60 sec at 72°C.  The PCR reaction was then analyzed using agarose gel 
electrophoresis and DNA staining with ethidium bromide.  
To verify the existence of HpaII restriction sites, digestion was performed using the 
methylation insensitive HpaII isochizomer MspI. Due to the absence of methylation 
insensitive isochizomers for the restriction enzymes BsaAI and TauI, the verification of the 
presence of specific restriction sites for those enzymes was performed using PCR products of 
the investigated HERV-K proviruses as substrates for digestion. 
To verify the assay, the 5'LTR of HERV-K 22q11 was subcloned into a TA-Cloning 
vector and in vitro methylation was performed by SssI DNA methyltransferase as described 
above. The differentially methylated vector was used for digestion and PCR-amplification as 
also described above. 
 
RESULTS 
High Levels of Spliced HERV-K mRNA in Human Melanoma Cell Lines 
In order to analyze HERV-K expression in a panel of melanoma cell lines comprising 
the previously analyzed cell lines SK-MEL-28, RA, TR, SchM, SchW and ZD (Buscher et al., 
2005; 2006) and the cell lines SK-MEL-13, SK-MEL-19, SK-MEL-24, and SK-MEL-37 not 
yet investigated, a SYBR-Green real-time RT-PCR specific for HERV-K env, rec and np9 
mRNA was developed. This method allows the amount of spliced env, rec and np9 mRNA to 
be estimated. The relative HERV-K expression was calculated by the 2(-delta delta Ct) 
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method (Livak and Schmittgen, 2001) in comparison with the HERV-K expression in the 
teratocarcinoma cell line GH known to express HERV-K mRNAs at a very high level 
(Buscher et al., 2005).  Five of the eleven cell lines showed high levels of HERV-K env and 
rec mRNA expression (Fig. 1A). These cell lines also showed increased (but not high) levels 
of np9 mRNA (0.2% of the expression in GH cells) (Fig. 1A). The other six cell lines showed 
a very low expression of HERV-K comparable with the expression of HERV-K in the human 
embryonic kidney cell line HEK-293. 
  
High LTR Activity in Melanoma Cell Lines Correlated with High HERV-K 
Expression 
To analyze the regulation of transcription initiation (one of the most important 
regulatory events in human gene expression) the melanoma cell lines SK-MEL-13, SK-MEL-
19, and SchM (characterized by high HERV-K expression) as well as SK-MEL-24, SK-MEL-
37, and RA (characterized by low HERV-K expression) were analyzed. Regulation of 
transcription initiation may be accomplished by two basic principles. First, by the availability 
of promoter specific TFs that enhance the binding of RNA-polymerases (RNAP) and second, 
by the presence of open promoter structures that enable the binding of the activated TFs to the 
promoter. To define the presence of HERV-K specific TFs in melanoma cell lines, the 
HERV-K 5'LTR activity was measured using a dual luciferase reporter gene assay. All cell 
lines (except cell line RA which showed only about 20% of luciferase activity in comparison 
to the other cell lines) showed nearly the same luciferase activity, when the pGL3b-control 
vector was used, indicating nearly equal transcriptional activities (Fig. 1B). When a luciferase 
expression vector was used, which contained a HERV-K 5’LTR as a promoter, all cell lines 
with high HERV-K expression showed a significant higher luciferase activity than cell lines 
with only a basal level of HERV-K transcription, indicating that HERV-K-expressing cell 
lines had a different level of activated HERV-K-specific TFs compared to cell lines not 
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expressing HERV-K (Fig. 1B). These results raised the question whether high HERV-K LTR 
activities were typical for melanomas or whether only a few tumor cell lines express sufficient 
TFs able to activate HERV-K LTRs. To answer this question a set of another ten melanoma 
cell lines was randomly selected without knowing their level of HERV-K mRNA expression. 
These cell lines were investigated for LTR activity as shown above. In none of the ten cell 
lines was high LTR activity detected (Fig. 1C), suggesting that high HERV-K LTR activity is 
not a general property of melanoma cells but may be the result of disturbed regulation during 
tumor progression. 
 
The LTR Activity in Melanoma Cell Lines Depends Directly on the CpG 
Methylation Status of the 5'LTR.  
As mentioned above, regulation of gene transcription depends not only on the 
availability of activated TFs but is also regulated by the accessibility of the activated TFs and 
the RNAP II to the promoter. It had been shown previously that the promoter activity of 
HERV-K(HML-2) 5'LTRs was reduced after CpG methylation in the teratocarcinoma cell 
line Tera-1 (Lavie et al., 2005). These data raised the question whether methylation also plays 
an important role in HERV-K silencing in melanoma. To answer this question, the HERV-K 
LTR-driven reporter gene construct pGL3-LTR was methylated in vitro using the CpG 
methyltransferase SssI (Fig. 2A). Using increasing amounts of methyltransferase higher levels 
of methylation were achieved. After transient transfection of these constructs into cell lines 
expressing HERV-K, all analyzed cell lines showed a loss of promoter activity dependent on 
the level of CpG-dinucleotide methylation. Cells that were transfected with plasmids showing 
nearly full methylation exhibited only basal levels of luciferase expression comparable with 
the LTR activity measured in cell lines not expressing HERV-K (Fig. 2B). These findings 
indicated that the assembly of TFs and the RNAP II on the HERV-K(HML-2) 5'LTR is 
directly or indirectly inhibited by CpG-methylation in melanomas. 
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Cell Lines Expressing HERV-K Showed a Lower LTR Methylation Level than 
Cell Lines With Low HERV-K Expression  
To analyze the methylation status of different HERV-K 5'LTRs in melanoma cell lines 
a methylation detection assay was established using three methylation sensitive restriction 
enzymes (see Materials and methods and supplemental Fig. 1A). To validate the assay, 
plasmids that contained the 5'LTR of HERV-K 22q11 methylated at increasing levels were 
used as a substitute of genomic DNA.  Digestion of the plasmid DNA by the restriction 
enzymes HpaII and BsaAI showed that strong and intermediately methylated sites could be 
detected. Using TauI for restriction only strong CpG methylation could be seen (supplemental 
Fig. 1 B). For a comprehensive analysis of the methylation status of HERV-K-5'LTRs in 
melanoma cell lines, specific primers for ten proviruses and two solo LTRs were designed. 
The 5'LTR methylation level was investigated for the HERV-K expressing cell lines GH, SK-
Mel-13 and SchM and for the cell lines HEK-293, SK-MEL-24 and RA, characterized by low 
expression of HERV-K. Thereby, low levels of methylation were found in the cell line GH 
and in the melanoma cell line SK-MEL-13. High levels of methylation were found in the cell 
line HEK-293 and in the melanoma cell lines SK-MEL-24 and RA (Table 1). Interestingly, in 
the melanoma cell line SchM, which showed an increased level of HERV-K-mRNA and a 
strong promoter activity, demethylation was only found for two proviruses and the two solo 
LTRs. Furthermore, demethylation of 5'LTRs was detected for almost all 5'LTR in the cell 
lines GH and SK-MEL-13, indicating a genome-wide demethylation of HERV-K 5’LTRs. 
Noticeable, a higher methylation status of the U5-region was observed for most of the 
investigated 5'LTRs in each cell line. 
 
Bisulfite Sequencing of the HERV-K108 5'LTR and 5'UTR  
For a detailed analyses of the methylation level of HERV-K(HML-2) 5’LTRs the first 
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locus of the provirus HERV-K-108 on 7p22 was selected. Our previous studies had shown 
that most HERV-K mRNAs expressed in SK-MEL-28 cells were derived from HERV-K-108 
(unpublished data). Using a modified bisulfite sequencing protocol, for the first time 
methylation in the R, U5 and 5' untranslated region of a single HERV-K(HML-2) provirus 
was analyzed. Whereas the cell line HEK-293 and peripheral mononuclear cells (PBMCs), 
both not expressing HERV-K, showed nearly total methylation of the investigated sequence 
(Fig. 3), strong demethylation was detected in the teratocarcinoma cell line GH. In this cell 
line methylation was only observed at single CpG sites in the U5 region and the 5'UTR. 
Whereas in cell lines expressing HERV-K demethylation of HERV-K-108 was observed in 
the whole investigated sequence (except SK-MEL-28 that showed some methylation of the 
last CpG-dinucleotides in the 5'UTR), cell lines with low levels of HERV-K mRNA showed 
stronger methylation of the U5 region and the 5'UTR. All melanoma cell lines not expressing 
HERV-K also showed demethylation in U3 and the starting R-region (Fig. 3). These data 
confirm differences in methylation of HERV-K(HML-2) 5'LTRs between cell lines 
expressing or not expressing HERV-K and that methylation negatively correlates with HERV-
K expression. 
  
5-aza-dC Stimulates HERV-K Expression in Melanoma Cell Lines.  
To demonstrate that CpG methylation is an epigenetic silencer of HERV-K 
transcription in melanoma cell lines, control and melanoma cell lines were treated with the 
demethylating agent 5-aza-dC. After treatment, changes in HERV-K expression were 
measured by quantitative real-time RT-PCR using primers for env, rec and np9. Thereby, 
treatment of GH cells with 5-aza-dC resulted in a slight increase of expression of these genes 
(Fig. 4A). In contrast, a very strong increase of HERV-K env and rec and a slight increase of 
np9 expression were detected in HEK-293 cells (Fig. 4B), in which HERV-K is normally not 
expressed. Similar results were obtained when treating melanoma cell lines. In the HERV-K-
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expressing melanoma cell lines SK-MEL-13 and SK-MEL-19 no changes in HERV-K 
expression were observed after treatment with 5-aza-dC (with exception of a small increase of 
np9 mRNA in SK-MEL-13). On the other hand, melanoma cell lines with a low level of 
HERV-K expression showed a significant increase in the levels of env, rec and np9 mRNA. 
This increase was also measured in the cell line RA but it was not as strong as in cell lines, 
which do not express HERV-K. This finding correlates with the low promoter activity shown 
in RA cells. In contrast, a clear increase of HERV-K env and rec but not np9 expression was 
observed after treatment of the cell line SchM, which highly expressed HERV-K. But, as 
shown above, the cell line SchM exhibited a much stronger LTR methylation in comparison 
with SK-MEL-13 (Table 1). In addition to DNA methylation, initiation of HERV-K 
transcription may also be regulated by complex modifications of histone molecules. Thereby 
acetylation of histones results in open and transcriptionally active chromatin. In order to 
investigate the influence of histone acetylation on the transcriptional activity of HERV-
K(HML-2), melanoma cell lines were treated with the histone deacetylase inhibitor TSA. 
Only HEK-293 cells exhibited increased HERV-K-expression as a result of TSA treatment. 
Co-treatment of HEK-293 cells with 5-aza-dC and TSA showed a synergistic effect on the 
expression of env, rec and np9. Such effects were not observed when melanoma cell lines 
were treated, indicating that transcriptional regulation by histone acetylation may not be a key 
regulatory element in HERV-K expression.  
 
5-aza-dC Does not Increase the Level of LTR Activating TFs.  
The activation of HERV-K-expression by 5-aza-dC in cell lines with low expression 
of HERV-K may be due to the global demethylation of the genome and therefore due to the 
activation of HERV-K specific TFs or due to the demethylation of HERV-K-5'LTRs. To 
discriminate between both possibilities an indirect analysis was performed using transient 
transfection of an unmethylated LTR reporter gene construct followed by 5-aza-dC treatment. 
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In parallel, untransfected cells were treated with the same medium that was used for treatment 
of the transfected cells (containing 5-aza-dC or not). All cell lines treated with 5-aza-dC 
showed an increase of rec expression in comparison to untreated controls indicating a 
successful treatment with 5-aza-dC (Fig. 5B). In contrast to that, no significant changes in 
LTR activity was observed as measured by luciferase activity. The cell line SK-MEL-37 
exhibited a slight increase in LTR activity after 5-aza-dC treatment by a factor of two (Fig. 
5A), which cannot reflect the increase of HERV-K-expression measured by real-time PCR 
(twelvefold).   
 
DISCUSSION 
The overall prognosis of patients with advanced melanoma is very poor due to the lack 
of effective treatment and late detection of the tumor. Therefore reliably detection methods 
and meaningful tumor markers are required (Riker et al., 2007). To analyze the tumor-specific 
expression of HERV-K and to address HERV-K proteins as putative targets for cancer 
immunotherapy and as tumor markers, the transcriptional regulation of HERV-K in 
melanomas was investigated. Cell lines with high and cell lines with low expression of 
HERV-K, especially of the genes encoding the immunosuppressive transmembrane envelope 
protein and the two accessory proteins Rec and Np9 were identified. Using different assays, a 
clear correlation between the methylation level in the LTR of ten different proviral LTR and 
the expression of HERV-K specific mRNA was shown. The extent of methylation of the 
HERV-K108 5'LTR and 5'UTR was analyzed in great detail, because this provirus was found 
to be expressed abundantly in melanoma cells (unpublished data). Treatment with the 
demethylating agent 5-aza-dC resulted in increased levels of HERV-K expression in cells 
previously not expressing HERV-K and it was shown that this increase is not the result of 
transcription factor activation. High levels of HERV-K transcription were the result of a 
disturbed genetic and epigenetic regulation of expression. But these results also demonstrated 
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that high HERV-K LTR activity is not a general property of melanoma cells.  
One important requirement for high levels of HERV-K(HML-2) expression in 
melanomas is a high promoter activity. This conclusion is based on two observations. First, 
none of the melanoma cell lines with a low HERV-K mRNA level showed a high luciferase 
expression after transfection with the unmethylated HERV-K LTR reporter gene construct. 
Second, none of the randomly chosen melanoma cell lines showed a strong luciferase activity 
after luciferase HERV-K LTR plasmid transfection – both indicating low levels of HERV-K-
specific TFs in those cell lines. Therefore high promoter activities as found in cell lines with 
high levels of HERV-K mRNA (Fig. 1A) are most likely the result of increased activation of 
HERV-K specific TFs. Strong LTR activity in melanomas may be the result of higher 
expression of the HERV-K activating TFs YY1 (Knossl et al., 1999) or AP1 (Kwun et al., 
2002). Interestingly, there are higher levels of YY1 mRNA in SK-MEL-28 cells compared 
with normal skin (Su et al., 2004).  
In addition to a transcriptional regulation via TFs there is an epigenetic regulation by 
CpG-dinucleotide methylation (Lavie et al., 2005). Endogenous LTR elements are usually 
transcriptionally silenced by CpG methylation in somatic cells (Bestor, 2000) and strong 
DNA methylation was reported in fetal brain, fetal liver, placenta and adult peripheral 
leukocytes (Shen et al., 2006). In melanomas, HERV-K promoter activity depends directly on 
the methylation status of its 5'LTR (Fig. 2). This suggests that HERV-K activating TFs are 
sensitive to CpG methylation. For example it is known that the HERV-K activating 
transcription factor YY1 does not bind methylated DNA in vitro (Kim et al., 2003). 
Interestingly, demethylation of one or more HERV-K-5'LTRs was found in every cell line 
tested, but in cells with high HERV-K expression less methylation was observed than in cells 
with only a basal level of HERV-K expression, supporting the hypothesis of a methylation 
dependent regulation of HERV-K proviruses in melanoma. Especially in the cell lines GH and 
SK-MEL-13 with the highest HERV-K expression (Fig. 1A), demethylation was found for 
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nearly every tested 5'LTR indicating genome wide demethylation of HERV-K 5'LTRs. This is 
in line with the finding that these cell lines did not show an additional HERV-K activation 
after treatment with the demethylating agent 5-aza-dC. The reason for global demethylation in 
those cell lines could be a loss of maintaining methylation by the DNA methyltransferase-1 
(DNMT1) (Bestor, 2000; Howard et al., 2008). The loss of maintaining DNA methylation and 
genome wide demethylation could have driven tumor progression by activation of oncogenes 
or chromosomal destabilization (Howard et al., 2008; Daskalos et al., 2009). Analyzing the 
expression and functionality of the human DNA methyltransferases DNMT1, DNMT3a and 
DNMT3b and in parallel the expression of HERV-K(HML-2) could give an insight into the 
mechanism of HERV-K demethylation in melanoma. In contrast to the hypomethylated cell 
lines, the melanoma cell lines RA and SK-MEL-24 showed a strong methylation of the 
investigated 5'LTRs and an increase of HERV-K expression after treatment with 5DC. 
Nevertheless, HERV-K expression did not reach the mRNA level detectable in cell lines 
expressing HERV-K, presumably because of a deficit in activated HERV-K specific TFs, 
underlining the suggested two-step activation mechanism for HERV-K transcription by 
transcription factor activation and 5'LTR demethylation. Of special interest is the cell line 
SchM, the only line showing high HERV-K mRNA levels and high LTR activity on the one 
hand and high methylation of many 5'LTRs on the other. Furthermore, it was the only HERV-
K expressing cell line that showed an additional stimulation of HERV-K expression after 
treatment with 5-aza-dC.  Obviously 5-aza-dC demethylates still methylated LTRs which then 
allow the expression of HERV-K. This cell line clearly confirms that HERV-K proviruses are 
silenced by DNA methylation in melanoma. These data also indicate that LTR activating TFs 
do not influence the methylation status of methylated LTRs directly by a recruitment of 
enzymes that support DNA demethylation and chromatin opening. In a reverse conclusion, 
HERV-K LTR demethylation may be secondary to the loss of maintaining DNA-methylation. 
For the first time, using the bisulfite sequencing technique, the methylation status of a 
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complete HERV-K(HML-2) 5'LTR and the 5'UTR was analyzed. Demethylation of the U5 
region and the 5'UTR was found only in cell lines characterized by high HERV-K expression. 
This suggests that these regions may contain methylation dependent regulatory elements. 
Although most of the analyzes were performed using melanoma cell lines that may not 
reflect the entire in vivo situation in the primary tumor, in preliminary investigations a 
comparable high level of HERV-K expression was found in primary melanomas using real 
time PCR (data not shown). This indicates that the situation of HERV-K expression in 
melanoma cell lines is comparable to that in melanoma. 
 To summarize, high levels of HERV-K mRNA expression in melanomas are the result 
of two processes, namely upregulation of HERV-K activating TFs and a defect in maintaining 
LTR methylation. Both processes must occur in melanoma cells in order to induce a strong 
HERV-K(HML-2) expression, as seen for example in germ cell tumors. Therefore, high levels 
of HERV-K expression in melanomas might be a marker for genetical and epigenetical 
changes. 
Demethylation is obviously necessary for the expression of HERV-K. Since it is 
unlikely that HERV-K is able to demethylate its proviruses, the loss of methylation must be 
the result of genetic changes in the cell, e.g., a loss of DNMT1 activity. Therefore, the 
activation of HERV-K expression ought to be understood as a secondary event. The increase 
in demethylation may enhance expression of HERV-K mRNA as well as Env, Rec and Np9 
proteins.  Since there is preliminary evidence that Rec and Np9 may be involved in 
tumorigenesis (Galli et al., 2005), they may contribute to tumor induction. In addition, the 
expression of the immunosuppressive Env protein may contribute to tumor progression 
preventing tumor rejection by the immune system (Mangeney and Heidmann, 1998; 
Mangeney et al., 2001, 2005; Denner, 2010). In this context it is of great interest whether 
HERV-K proteins are good targets for cancer immunotherapy. Such investigations will help 
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Figure 1. Expression and promotor activity of HERV-K. (A) Expression of HERV-K 
mRNAs env, rec and np9 compared with their expression in GH cells. (B) Promoter 
activity in melanoma cell lines as measured by a dual luciferase reporter gene assay 
using the promotor-less plasmid pGL3-basic, the LTR driven plasmid pGL3b-LTR 
and the SV40 driven plasmid pGL3b-control. (C) Relative promotor activity in a panel 




Figure 2. Silencing of HERV-K promoter activity by in vitro methylation of CpG-
dinucleotides. (A) Analysis of the methylation status of the in vitro differentially 
methylated pGL3b-LTR plasmid using the methylation sensitive restriction enzyme 
HpaII and the methylation insensitive isochizomer MspI. Increasing amounts of SssI 
DNA methylase (0 U, 0.75 U, 2 U, 4 U) were used for the in vitro methylation reaction 
to increase the extend of methylation. (B) Inhibition of promotor activity of the HERV-
K(HML2) LTR by CpG methylation in GH cells and the melanoma cell lines SchM, 
SK-MEL-13 and SK-MEL-19. 
 
 
Figure 3. Bisulfite sequencing (BSS) of the entire 5’LTR of HERV-K108.  (A) 
Schematic presentation of the analyzed sequence, vertical lines indicate the location 
of CpG-dinucleotides. +1 indicates the first base pair of the 5’LTR (grey). (B) BSS of 
the control cell lines. Black spots indicate methylated CpG; white spots indicate 
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absence of methylation. (C) BSS of melanoma cell lines expressing HERV-K. (D) 
BSS of melanoma cell lines with low expression of HERV-K. 
 
Figure 4. Changes of HERV-K expression in control and melanoma cell lines after 
treatment with epigenetic agents. Cell lines were cultured in medium (untreated 
control) or drug containing medium (5-aza-dC, TSA or 5-aza-dC and TSA). After 3 
days cells were harvested, RNA was extracted and used for HERV-K env, rec and 
np9 quantification by real-time RT-PCR. (A) Relative changes of HERV-K expression 
in cell lines expressing HERV-K. (B) Relative changes of HERV-K expression in cell 
lines not expressing HERV-K. 
 
Figure 5. Promoter activity and rec expression in cells treated (+) or untreated (-) with 
the demethylating agent 5-aza-dC. (A) promotor activity of the HERV-K-5'LTR as 
measured by luciferase reporter gene assay. (B) Relative rec mRNA expression as 
measured by real-time RT-PCR. 
TABLE 1. HERV-K 5‘LTR CpG Methylation 
Genomic   Position of restriction   GH   HEK-293   SK-MEL-13   SchM   RA   SK-MEL-24 
 position   TauI BsaAI HpaII   TauI BsaAI HpaII   TauI BsaAI HpaII   TauI BsaAI HpaII   TauI BsaAI HpaII   TauI BsaAI HpaII   TauI BsaAI HpaII
                          
1q22  304 711 854       
1q23.3  n.r. 712 855            
3q12  305 718 610       
3q13  296 703 846       
5q13  296 693 n.r.                
5q33  305 712 855       
7p22  304 n.r. 854                   
11q22  304 711 854       
12q11  304 711 854       
22q11  304 711 854       
Solo 7p21  304 711 854       
Solo 19q13  304 711 854       
                                                       
                             
Note: 
 
Position of restriction indicates the localisation of the restriction recognition site 
relative to the first base pair of the specific 5'LTR.  
  n.r. means no restriction recognition site               
          




SUPPLEMENTARY TABLE 1. Primers Used for RT-PCR and PCR Investigations 
Name Chromosome Band Position of binding Sequence 5'-3' 
       
Cloning of the HERV-K108 5'LTR:      
       
K108 fw 7 7p22.1 4606821 - 4606840 TGACGTTTGGGCTTCTATCC 
K108 rev 7 7p22.1 4605303 - 4605323 CCATGGGCAAAATTGTTCTA  
       
Detection of the methylation status of HERV-K 5'LTRs:    
       
1q22 1 1q22 153872281 - 153872301 GCACCCTGGAAAGTAAAGGA 
1q23.3 1 1q23.3 158927019 - 158927038 CATGGGTCCTGGTAAAGTGG 
3q12 3 3q12.3 102893266 - 102893285 CTTCTCAGGTGTGGGAAGGA 
3q13 3 3q13.2 114235040 - 114235063 TTTCAGACTTTCCTATCTGACCTC 
5q13 5 5q13.3 30532008 - 30532027 CCTGGGATGCAAGTCTTGTT 
5q33 5 5q33.3 156026565 - 156026584 ACCCAACCTGCATGGTTTTT 
7p22 7 7p22.1 4606596 - 4606614 TACAGGAGTGCGCCATCAC 
11q22 11 11q22.1 101070927 - 101070947 CAACAAACACTTCCATGCTCA 
12q11 12 12q14.1 57017040 - 57017059 AAAACCAAAGGAACGTGCTG 
22q11 22 22q11.21 17306112 - 17306131 TACAGGCTGGACTGCACCTA 
Solo 7p21 7 7p21.1 16203829 - 16203850 CCAACACATAATGACTCCATCC 
Solo 19q13 19 19q13.13 43048582 - 43048601 CTGTGGCCCAAGCTGATACT 
K108 +961 rev multiple binding sites within the human genome TGTGTAGGGGCAACCCAC 
       
Real-time PCR:       
       
GUS-B fw 7 7q21.11  65070155 - 65070175 AAACGATTGCAGGGTTTCACC 
GUS-B rev 7 7q21.11  65066803 - 65066822 GCGTTTTTGATCCAGACCCA 
Pfor   multiple binding sites within the human genome CCAACGTGGAGGCTTTTCTCTAG  
PENV   multiple binding sites within the human genome AGGGAGACTTACCACCATTGATAC 
PREC   multiple binding sites within the human genome GGGTATACCTGCAGACACCATTG  
PNP9 multiple binding sites within the human genome TGGGTACACCTGCAGACATCTC 
       
Bisulfite-Sequencing:      
       
BSS-K108-183fw 7 7p22.1 4606719 - 4606740 TTGTTGTTTAGGTTGGAGTGT 
BSS-K108-40fw 7 7p22.1 4606576 - 4606597 TTTTAAGTAGTTAGGGTTATA 
BSS-K108+1306rev multiple binding sites within the human genome TTCCTTACCAATTCTTTTCCAA 
BSS-K108+1121rev multiple binding sites within the human genome ATTTACCCCATTATCACCCTAA 
             
       





Supplementary Figure 1. Analysis of the methylation status of different HERV-K(HML-2)-
5'LTR (A) schematic presentation of the 5'LTR of HERV-K(HML-2). Vertical bars show the 
presence of a CpG dinucleotide. Horizontal arrows indicate the PCR-primer binding sites.  (B) 
evaluation of the assay using differentially methylated plasmids containing the 5'LTR of 
HERV-K 22q11. Plasmids were digested with methylation sensitive endonucleases followed 
by PCR amplification using HERV-K 22q11 specific primers.  (C) analysis of the methylation 
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Suppl. Fig. 1 Stengel et al.
 
